Civitas Therapeutics, a US-based biopharmaceutical company with a lead program in Parkinson’s disease, has completed a $38m series B financing led by life sciences venture capital firm Bay City Capital and joined by new investors RA Capital, a US-based healthcare and life sciences investment firm, as well as an undisclosed investment fund; all existing investors participated, including Alkermes plc,  an Ireland-based biopharmaceutical company that focuses on central nervous system diseases, venture capital firm Canaan Partners, Ireland-based life sciences venture capital…